# Efficacy and Safety of AQX-1125 in Unstable COPD

> **NCT01954628** · PHASE2 · COMPLETED · sponsor: **Aquinox Pharmaceuticals (Canada) Inc.** · enrollment: 400 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** AQX-1125
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01954628
- **Lead sponsor:** Aquinox Pharmaceuticals (Canada) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-07
- **Final completion:** 2015-12
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954628, "Efficacy and Safety of AQX-1125 in Unstable COPD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01954628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*